000281845 001__ 281845
000281845 005__ 20251104093908.0
000281845 0247_ $$2doi$$a10.1111/jnc.70267
000281845 0247_ $$2ISSN$$a0022-3042
000281845 0247_ $$2ISSN$$a1471-4159
000281845 037__ $$aDZNE-2025-01224
000281845 082__ $$a610
000281845 1001_ $$0P:(DE-2719)9001120$$aBeschorner, Natalie$$b0$$eFirst author$$udzne
000281845 245__ $$aAmyloid‐β Seeds in Alzheimer's Disease: Research Challenges and Implications
000281845 260__ $$aOxford$$bWiley-Blackwell$$c2025
000281845 3367_ $$2DRIVER$$aarticle
000281845 3367_ $$2DataCite$$aOutput Types/Journal article
000281845 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1762245213_2549$$xReview Article
000281845 3367_ $$2BibTeX$$aARTICLE
000281845 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281845 3367_ $$00$$2EndNote$$aJournal Article
000281845 520__ $$aThe amyloid cascade hypothesis, proposed over 30 years ago, places amyloid-β (Aβ) at the center of Alzheimer's disease (AD) pathogenesis. Though controversial, recent clinical successes with Aβ-targeting therapies have reinforced its importance. However, these treatments have shown only modest clinical benefits in line with a two-stage AD progression: an early phase driven by Aβ-seed and a later phase that progresses at least partly independently of Aβ. Evidence of Aβ seed transmission in humans raises both therapeutic potential and biosafety concerns. This review explores current understanding of Aβ seeds, including challenges in studying such seeds, model systems to study Aβ seeds, and biosafety issues when working with Aβ seeds.
000281845 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281845 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000281845 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000281845 7001_ $$0P:(DE-2719)9001899$$aXu, Ying$$b1
000281845 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b2
000281845 7001_ $$0P:(DE-2719)2812802$$aRuiz-Riquelme, Alejandro$$b3
000281845 773__ $$0PERI:(DE-600)2020528-4$$a10.1111/jnc.70267$$gVol. 169, no. 11, p. e70267$$n11$$pe70267$$tJournal of neurochemistry$$v169$$x0022-3042$$y2025
000281845 8564_ $$uhttps://pub.dzne.de/record/281845/files/DZNE-2025-01224.pdf$$yRestricted
000281845 8564_ $$uhttps://pub.dzne.de/record/281845/files/DZNE-2025-01224.pdf?subformat=pdfa$$xpdfa$$yRestricted
000281845 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001120$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000281845 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001899$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000281845 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000281845 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281845 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000281845 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-01$$wger
000281845 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-01$$wger
000281845 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROCHEM : 2022$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000281845 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-01
000281845 9201_ $$0I:(DE-2719)1013020$$kAG Petzold$$lVascular Neurology$$x0
000281845 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x1
000281845 980__ $$ajournal
000281845 980__ $$aEDITORS
000281845 980__ $$aVDBINPRINT
000281845 980__ $$aI:(DE-2719)1013020
000281845 980__ $$aI:(DE-2719)1210001
000281845 980__ $$aUNRESTRICTED